Catalent Executive and Leadership Team

Christopher Hajjar, the Vice President, Finance & Biologics, Corporate Financial Planning & Analysis Segment Chief Financial Officer at Catalent, directs financial strategy and planning, with a specific focus on the biologics segment. This executive role involves overseeing financial operations, budgeting, and forecasting to support Catalent's extensive capabilities in drug development and manufacturing. Managing the financial planning and analysis functions, Christopher Hajjar ensures robust fiscal management across the organization, enabling strategic investments in new technologies and capacity expansions. The Segment Chief Financial Officer responsibilities include providing critical financial insights to guide decision-making for personalized medicines and blockbuster drugs, reinforcing Catalent's position as a leading Contract Development and Manufacturing Organization. By optimizing financial performance and resource allocation, Hajjar directly contributes to Catalent's sustained growth and its mission to deliver life-changing therapies to patients globally.

Matti Masanovich, the Senior VP & Chief Financial Officer at Catalent, directs the company's overall financial strategy, planning, and management. This critical leadership role ensures the fiscal health and strategic allocation of resources to support Catalent's global operations and growth initiatives. Overseeing all financial functions, Matti Masanovich provides essential insights into investment opportunities, operational efficiencies, and risk management, underpinning Catalent's position as a premier Contract Development and Manufacturing Organization. The Chief Financial Officer's purview includes managing capital structure, investor relations, and financial reporting to stakeholders worldwide. By driving financial discipline and strategic financial planning, Masanovich directly contributes to Catalent's ability to optimize product development, full life-cycle supply, and its commitment to delivering innovative therapies, including personalized medicines, to patients globally.

Ricky Hopson, the Group President, Clinical and Specialty Services and Chief of Staff at Catalent, directs critical clinical trial services and specialized offerings. This leadership role ensures the seamless integration of development sciences and delivery technologies across the organization, supporting partners in optimizing product launches and lifecycle management. Overseeing key operational units, Ricky Hopson drives efficiency and innovation within the clinical services division, directly impacting the speed and success of patient therapies reaching the market. The Chief of Staff function involves close collaboration with executive leadership to align strategic initiatives and operational execution, ensuring Catalent's global operations meet the complex demands of the pharmaceutical, biotech, and consumer health sectors. This executive's purview extends to enhancing the company's capabilities in personalized medicines and blockbuster drug development, reinforcing Catalent's status as a premier Contract Development and Manufacturing Organization.

Barry Littlejohns, the President, Advanced Delivery Technologies at Catalent, leads the innovation and commercialization of cutting-edge drug delivery systems. This executive role is fundamental to Catalent's strategy of providing partners with advanced solutions for optimizing product development and enhancing therapeutic efficacy. Overseeing the development and deployment of novel technologies, Barry Littlejohns ensures Catalent remains at the forefront of the industry, supporting the creation of personalized medicines and complex drug formulations. The focus of Advanced Delivery Technologies includes improving patient outcomes through enhanced bioavailability, targeted delivery, and patient compliance. By driving technological advancements in drug delivery, Littlejohns directly contributes to Catalent's reputation as a preferred Contract Development and Manufacturing Organization and its mission to bring vital treatments to patients worldwide.

David McErlane, the Group President, Biologics at Catalent, directs the company's comprehensive biologics development and manufacturing operations. This leadership position is critical for supporting partners in bringing complex biologic therapies to market, leveraging Catalent's deep expertise in this rapidly evolving sector. Overseeing all aspects of biologics production, David McErlane ensures adherence to the highest quality standards and drives operational excellence to meet global demand. The Group President's responsibilities include advancing Catalent's capabilities in areas such as cell and gene therapies, monoclonal antibodies, and other advanced biologic modalities. By optimizing the development and manufacturing lifecycle for biologics, McErlane directly contributes to Catalent's role as a premier Contract Development and Manufacturing Organization and its commitment to enabling patient access to life-changing treatments.

Trish Hunt, the Group VP & Chief Marketing Officer at Catalent, architects and executes comprehensive marketing strategies that elevate the company's global brand presence. This leadership position involves defining market positioning and driving demand for Catalent's extensive capabilities in development sciences, delivery technologies, and multi-modality manufacturing. Overseeing all marketing functions, Trish Hunt ensures consistent messaging across diverse partner segments, including pharma, biotech, and consumer health, highlighting Catalent's role as a preferred Contract Development and Manufacturing Organization. The Chief Marketing Officer's responsibilities include spearheading market intelligence initiatives and translating insights into actionable growth plans, particularly for personalized medicines and blockbuster drugs. By fostering strong partner relationships and communicating the value proposition of Catalent's services, Hunt directly contributes to the company's market leadership and expansion into new therapeutic areas.

Shouryadeep Srivastava, the Chief Medical Officer, Consulting & Chief Marketing Officer at Catalent, provides critical medical and strategic marketing leadership. This dual role involves guiding consulting services with deep clinical insights while also shaping the company's market communication and brand strategy. Overseeing the medical advisory function, Shouryadeep Srivastava ensures that Catalent's development and manufacturing solutions align with the latest scientific advancements and regulatory requirements, supporting partners in bringing innovative therapies to patients. The Chief Marketing Officer aspect of this position focuses on articulating Catalent's value proposition in personalized medicines and blockbuster drugs to a global audience. By integrating medical expertise with marketing acumen, Srivastava drives strategic initiatives that enhance Catalent's reputation as a leading Contract Development and Manufacturing Organization and fosters growth across its diverse service offerings.

Charles Lickfold, the Senior Vice President, Chief Technology Officer at Catalent, spearheads technological innovation and infrastructure development across the organization. This pivotal role involves defining and implementing the company's technology roadmap, ensuring Catalent maintains its edge in development sciences, delivery technologies, and advanced manufacturing processes. Overseeing the integration of cutting-edge technologies, Charles Lickfold drives efficiency and scalability in operations, supporting the complex needs of pharmaceutical, biotech, and consumer health partners. The Chief Technology Officer's focus extends to enhancing Catalent's capabilities in areas such as personalized medicines and novel drug delivery systems. By championing technological advancements, Lickfold directly contributes to Catalent's position as a preferred Contract Development and Manufacturing Organization and its ability to optimize product development and full life-cycle supply for patients worldwide.

Kassandra Walsh, the Senior Account Director & Chief Revenue Officer at Catalent, drives revenue generation and manages key client relationships across the pharmaceutical, biotech, and consumer health sectors. This leadership position is central to expanding Catalent's market share and ensuring partner success through optimized product development and supply chain solutions. Overseeing sales strategies and revenue targets, Kassandra Walsh works closely with commercial teams to articulate the value of Catalent's broad expertise in development sciences and delivery technologies. The Chief Revenue Officer's focus includes fostering long-term partnerships and identifying new opportunities for growth, particularly in the areas of personalized medicines and blockbuster drugs. By aligning revenue objectives with client needs, Walsh directly contributes to Catalent's standing as a preferred Contract Development and Manufacturing Organization and its mission to bring critical therapies to patients worldwide.

Lisa Evoli, the Senior Vice President and Chief Human Resources Officer at Catalent, leads the strategic development and execution of human capital initiatives across the global organization. This executive role is crucial for attracting, developing, and retaining the talent necessary to support Catalent's mission as a leading Contract Development and Manufacturing Organization. Overseeing all HR functions, Lisa Evoli ensures that robust talent management programs are in place to foster a culture of innovation and operational excellence, vital for optimizing product development and life-cycle supply. The Chief Human Resources Officer's responsibilities include shaping employee engagement strategies and driving organizational effectiveness, particularly in supporting specialized areas like personalized medicines and advanced manufacturing. By cultivating a skilled and motivated workforce, Evoli directly contributes to Catalent's ability to serve its partners and deliver life-changing therapies to patients worldwide.